Regeneron Pharmaceuticals (REGN) Change in Receivables (2009 - 2026)

Regeneron Pharmaceuticals has reported Change in Receivables for 18 years, with the latest figure at -$1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables rose 99.82% year-over-year to -$1.2 million; the trailing twelve-month figure through Mar 2026 stood at $158.5 million (down 53.79% YoY), and the FY2025 full-year result was -$498.1 million, down 189.91% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.2 million, down from $51.2 million in the prior quarter.
• The five-year high for Change in Receivables was $494.1 million in Q2 2024, with the low at -$1.2 billion in Q1 2022.
• Average Change in Receivables over 5 years is -$18.5 million, with a median of $51.2 million recorded in 2025.
• Year-over-year, Change in Receivables sank 2154.03% in 2022 and soared 18200.0% in 2024.
• Tracing REGN's Change in Receivables over 5 years: stood at -$219.6 million in 2022, then jumped by 137.66% to $82.7 million in 2023, then surged by 42.44% to $117.8 million in 2024, then plunged by 56.54% to $51.2 million in 2025, then sank by 102.34% to -$1.2 million in 2026.
• The last three Change in Receivables figures came in at -$1.2 million (Q1 2026), $51.2 million (Q4 2025), and $80.3 million (Q3 2025), per Business Quant data.

Peer Comparison